Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07499232 · ClinicalTrials.gov registry record · Phase 3
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 3 study, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 530
- Enrollment target
NCT07499232 is a Phase 3 study that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 530 participants.
The verdict
NCT07499232, a Phase 3 study, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 530 participants
- Enrollment target
Study Summary
The purpose of this study is to assess how well guselkumab works when compared to risankizumab in participants with moderately to severely active Crohn's Disease (CD; a long-term condition causing severe inflammation of the intestinal tract).
Interventions
- DRUG Guselkumab
- DRUG Risankizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 530 participants |
| Start Date | 2026-04-21 |
| Est. Completion | 2030-12-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07499232
The ClinicalTrials.gov registry entry for NCT07499232 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 530 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Guselkumab is the first listed.
NCT07499232 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07499232 about?
NCT07499232 is a clinical study titled "A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease". The purpose of this study is to assess how well guselkumab works when compared to risankizumab in participants with moderately to severely active Crohn's Disease (CD; a long-term condition causing severe inflammation of the intestinal tract).
What is the current status of trial NCT07499232?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 530 participants. The study started on 2026-04-21. Estimated completion is 2030-12-11.
What interventions are being tested in trial NCT07499232?
The interventions under investigation include: Guselkumab (DRUG), Risankizumab (DRUG).
Who is sponsoring clinical trial NCT07499232?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.